$22.97 Million in Sales Expected for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) This Quarter

Equities research analysts expect that Xeris Biopharma Holdings, Inc. (NASDAQ:XERSGet Rating) will report sales of $22.97 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Xeris Biopharma’s earnings. The highest sales estimate is $24.10 million and the lowest is $22.28 million. Xeris Biopharma reported sales of $8.05 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 185.3%. The firm is scheduled to issue its next earnings report on Monday, January 1st.

On average, analysts expect that Xeris Biopharma will report full year sales of $112.18 million for the current fiscal year, with estimates ranging from $108.52 million to $116.80 million. For the next fiscal year, analysts anticipate that the business will report sales of $162.37 million, with estimates ranging from $146.10 million to $197.90 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Xeris Biopharma.

Xeris Biopharma (NASDAQ:XERSGet Rating) last released its quarterly earnings results on Thursday, March 10th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.21). Xeris Biopharma had a negative return on equity of 305.33% and a negative net margin of 248.68%. The company had revenue of $21.43 million for the quarter, compared to analyst estimates of $20.72 million. During the same quarter last year, the company earned ($0.41) EPS.

A number of research firms have commented on XERS. SVB Leerink cut their price objective on shares of Xeris Biopharma from $8.00 to $6.00 and set an “outperform” rating for the company in a report on Wednesday, February 16th. Zacks Investment Research cut shares of Xeris Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, January 20th. HC Wainwright reissued a “buy” rating and issued a $6.00 price target (down previously from $8.00) on shares of Xeris Biopharma in a research note on Friday, March 11th. Finally, Mizuho dropped their price target on shares of Xeris Biopharma from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, March 16th.

In related news, insider Steven Prestrelski sold 11,228 shares of the stock in a transaction that occurred on Tuesday, February 22nd. The shares were sold at an average price of $2.42, for a total transaction of $27,171.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.01% of the company’s stock.

Several large investors have recently bought and sold shares of XERS. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Xeris Biopharma in the 1st quarter valued at approximately $28,000. BlackRock Inc. boosted its position in Xeris Biopharma by 17.7% in the 4th quarter. BlackRock Inc. now owns 1,795,513 shares of the company’s stock valued at $5,261,000 after buying an additional 269,705 shares during the period. Wells Fargo & Company MN boosted its position in Xeris Biopharma by 355.1% in the 4th quarter. Wells Fargo & Company MN now owns 11,679 shares of the company’s stock valued at $34,000 after buying an additional 9,113 shares during the period. Goldman Sachs Group Inc. boosted its position in Xeris Biopharma by 83.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 227,691 shares of the company’s stock valued at $667,000 after buying an additional 103,507 shares during the period. Finally, Parametric Portfolio Associates LLC purchased a new position in Xeris Biopharma in the 4th quarter valued at approximately $191,000. 46.52% of the stock is owned by hedge funds and other institutional investors.

XERS opened at $2.42 on Tuesday. The firm has a market cap of $160.92 million and a P/E ratio of -1.59. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.57 and a current ratio of 1.80. Xeris Biopharma has a twelve month low of $1.77 and a twelve month high of $4.98. The stock’s 50-day moving average is $2.53.

About Xeris Biopharma (Get Rating)

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Read More

Get a free copy of the Zacks research report on Xeris Biopharma (XERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xeris Biopharma (NASDAQ:XERS)

Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.